Dr. Jimmy Van Den Eynden 

Current Position

2004-2010

PhD student and teaching assistent in neurophysiology at the Faculty of Medicine.
University Hasselt/transnationale Universiteit Limburg, Campus Diepenbeek
Agoralaan - Gebouw D
B-3590 Diepenbeek
Belgium
Tel.:+32-11-268549

Former position

2003-2004: Nuclear Medicine (physician in training) at UZ Gasthuisberg, Leuven.

University Education

1996-1999: Preclinical years of Medicine at the University Hasselt, Campus Diepenbeek.

1999-2003: Clinical years of Medicine at the KULeuven.

2002-2004: Academic Teaching Education at the faculty of Medicine at the KULeuven

Publications 

Van den Eynden J, Lannoo L, Amant F, Stroobants S, Vergote I. De schildwachtklierprocedure bij de behandeling van het vulvacarcinoom: eerste resultaten bij een reeks van 32 patiënten. Tijdschrift voor geneeskunde, 59(19):1169-1178, 2003.

Van Laere K, De Ceuninck L, Dom R, Van den Eynden J, Vanbilloen B, Dupont P, Bormans G, Maes A, Verbruggen A, Mortelmans L. Dopamine Transporter SPECT using Fast Kinetic Ligands: 123I-FP-β-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 31:1119-1127, 2004.

K. Baete, J. Nuyts, K. Van Laere, W. Van Paesschen, S. Ceyssens, L. De Ceuninck, O. Gheysens, M. Kelles, J. Van den Eynden, P. Suetens and P. Dupont. Evaluation of Anatomy Based Reconstruction for Partial Volume Correction in Brain FDG-PET. Neuroimage 23:305-317, 2004.

Oral presentations

Scientific Meeting of the Belgian Society of Nuclear Medicine, Brussels 12 June 2004: J. Van den Eynden, P. Dupont, R. Dom, L. De Ceuninck, B. Vanbilloen, A. Verbruggen, L. Mortelmans, K. Van Laere.  Discriminant analysis of perfusion and dopamine transporter SPECT in the differential diagnosis of progressive supranuclear palsy, multiple system atrophy and dementia with Lewy bodies.

Scientific Meeting of the Belgian Society of Nuclear Medicine, Brussels 13 December 2003: The Sentinel Node Procedure in Vulvar cancer.

Poster Presentations

Society of Nuclear Medicine, 51st annual meeting, Philadelphia, June 2004: J. Van den Eynden, L. De Ceuninck, R. Dom, P Dupont, L Mortelmans, K. Van Laere. The clinical spectrum of early Parkinson's Disease : a multitracer study in drug-naïve patients with and without resting tremor, in comparison to essential tremor.

National Symposium of Nuclear Medicine, Knokke, May 2003: Van den Eynden J, Lannoo J, Amant F, Stroobants S, Vergote I. The sentinel node procedure in the treatment of vulvar cancer: primary results in 32 patients.

Other abstracts he participated in

J. Van den Eynden, P. Dupont, R. Dom, L. De Ceuninck, B. Vanbilloen, A. Verbruggen, L. Mortelmans, K. Van Laere.  Discriminant analysis of perfusion and dopamine transporter SPECT in the differential diagnosis of progressive supranuclear palsy, multiple system atrophy and dementia with Lewy bodies. (Oral presentation at the yearly congress of the European Association of Nuclear Medicine, Helsinki, September 2004; Published in Eur J Nucl Med 31(S2): S247-248, 2004)

De Ceuninck L, Van Laere K, Dom R, Van den Eynden J, Vanbilloen B, Dupont P, Bormans G, Verbruggen A, Mortelmans L. I-123 FP-CIT is More Sensitive than Tc-99m TRODAT-1 in Differential Diagnosis and Follow-Up in Early Parkinson’s disease. (Oral presentation at the yearly congress of the European Association of Nuclear Medicine, Amsterdam, August 2003; Published in Eur J Nucl Med 30(S2):S157, 2003)

D. Beque, E. Lauwers, J. Nuyts, G. Bormans, P. Vermaelen, J. Van den Eynden, L. Mortelmans, Z. Debyser, V. Baekelandt, K. Van Laere. MicroSPECT validation of a rodent model for Parkinson's disease by lentiviral vector-mediated overexpression of alpha-synuclein. (Posterpresentation at the 51st annual meeting of the Society of Nuclear Medicine, Philadelphia, June 2004)

K Van Laere, E Lauwers, D Beque, J Nuyts, J Van den Eynden, B Vanbilloen, L Mortelmans, A Verbruggen, B. Nuttin, G Bormans, Z Debyser, V Baekelandt. Quantitative comparison of 123I-FP-CIT microSPECT dopamine transporter binding and histology in a rodent model for Parkinson’s disease by lentiviral vector-mediated overexpression of alpha-synuclein. (Oral presentation at the yearly congress of the European Association of Nuclear Medicine, Helsinki, September 2004)